Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole once-weekly for acute schizophrenia
2022-500583-36-00Phase 3Authorised
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Brexpiprazole once-weekly with Placebo (2 arms). Primary endpoint: Mean change from baseline in PANSS total score at Week 6. Planned start May 2023; status: authorised.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2022-500583-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500583-36-00.